{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:43:46Z","timestamp":1789559026403,"version":"build-2803163510"},"reference-count":22,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T00:00:00Z","timestamp":1573776000000},"content-version":"vor","delay-in-days":1293,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1093\/annonc\/mdw026","type":"journal-article","created":{"date-parts":[[2016,1,23]],"date-time":"2016-01-23T02:31:34Z","timestamp":1453516294000},"page":"895-901","source":"Crossref","is-referenced-by-count":25,"title":["Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era"],"prefix":"10.1016","volume":"27","author":[{"given":"C.Y.","family":"Cheah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Chihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.E.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.J.","family":"Nastoupil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Phansalkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.B.","family":"Hagemeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.E.","family":"Fayad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.R.","family":"Westin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Oki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Fanale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.E.","family":"Romaguera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.L.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Turturro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Samaniego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.S.","family":"Neelapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.H.","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdw026_bb0010","series-title":"WHO classification of tumors of the hematopoeitic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"key":"10.1093\/annonc\/mdw026_bb0015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"10.1093\/annonc\/mdw026_bb0020","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2012.45.0866","article-title":"R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 Trial conducted by the Fondazione Italiana Linfomi","volume":"31","author":"Federico","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw026_bb0025","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdw026_bb0030","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdw026_bb0035","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/annonc\/mdv102","article-title":"A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma","volume":"26","author":"Witzig","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw026_bb0040","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1182\/blood-2014-11-567792","article-title":"Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities","volume":"125","author":"Kritharis","year":"2015","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdw026_bb0045","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S1470-2045(14)70455-3","article-title":"Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial","volume":"15","author":"Fowler","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw026_bb0050","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.799.799","article-title":"Rituximab plus lenalidomide improves the complete remission rate in comparison with rituximab monotherapy in untreated follicular lymphoma patients in need of therapy. Primary endpoint analysis of the randomized phase-2 trial SAKK 35\/10","volume":"124","author":"Kimby","year":"2014","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdw026_bb0055","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.8521","article-title":"CALGB 50803 (Alliance): a phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma","volume":"32","author":"Martin","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw026_bb0060","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.1999.17.1.268","article-title":"Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy","volume":"17","author":"Czuczman","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw026_bb0065","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw026_bb0070","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdw026_bb0075","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/cncr.28659","article-title":"The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States","volume":"120","author":"Nastoupil","year":"2014","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdw026_bb0080","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.3052.3052","article-title":"Bendamustine plus rituximab followed by rituximab maintenance for patients with untreated advanced follicular lymphomas. Results from the StiL NHL 7-2008 Trial (MAINTAIN trial) (ClinicalTrials.gov Identifier: NCT00877214)","volume":"124","author":"Rummel","year":"2014","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdw026_bb0085","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.509.509","article-title":"Updated 6 year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline immunochemotherapy","volume":"122","author":"Salles","year":"2013","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdw026_bb0090","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1182\/blood-2015-02-628362","article-title":"Maintenance rituximab every 2 months is more toxic than every 3 months in patients with non-Hodgkin lymphoma","volume":"125","author":"Rashidi","year":"2015","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdw026_bb0095","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.3109\/10428194.2013.839787","article-title":"A systematic review of comparative schedule-related toxicities with maintenance rituximab in follicular and mantle cell lymphomas","volume":"55","author":"Nabhan","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdw026_bb0100","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.510.510","article-title":"Early relapse of follicular lymphoma after R-CHOP uniquely defines patients at high risk for death: an analysis from the National Lymphocare Study","volume":"122","author":"Casulo","year":"2013","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdw026_bb0105","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw026_bb0110","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood-2015-01-621375","article-title":"Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS)","volume":"126","author":"Wagner-Johnston","year":"2015","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdw026_bb0115","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.3109\/10428194.2014.885513","article-title":"Chemoimmunotherapy resistant follicular lymphoma: predictors of resistance, association with transformation and prognosis","volume":"55","author":"Mozessohn","year":"2014","journal-title":"Leuk Lymphoma"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419374101?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419374101?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T09:08:28Z","timestamp":1624698508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419374101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S0923753419374101"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdw026","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]}}}